Cystatin 6蛋白在哈萨克族食管鳞癌组织中的表达及其意义

doi:10.3969/j.issn.1004-616x.2022.06.004

癌变·畸变·突变 ›› 2022, Vol. 34 ›› Issue (6): 429-433,438.doi: 10.3969/j.issn.1004-616x.2022.06.004

• 论著 • 上一篇

Cystatin 6蛋白在哈萨克族食管鳞癌组织中的表达及其意义

李子垚¹, 张海平¹, 买地尼也提·尼亚孜², 居来提·艾尼瓦尔¹, 张力为¹, 伊地力斯·阿吾提^1,2

1. 新疆医科大学第一附属医院胸外科, 新疆乌鲁木齐 830054;
2. 新疆医科大学第一附属医院临床医学研究院省部共建中亚高发病成因与防治国家重点实验室, 新疆乌鲁木齐 830054

收稿日期:2022-06-20 修回日期:2022-10-22 发布日期:2022-12-03
通讯作者: 伊地力斯·阿吾提
作者简介:李子垚，E-mail：1980162874@qq.com。
基金资助:
国家自然科学基金(81960498);国家重点实验室开放课题(SKL-HIDCA-2021-21)

Clinicopathological significance of cystatin 6 protein expression in Kazakh esophageal squamous cell carcinoma

LI Ziyao¹, ZHANG Haiping¹, MADINIYET·Niyaz², JULATI·Ainiwaer¹, ZHANG Liwei¹, EDRIS·Awut^1,2

1. Department of Thoracic Surgery, the First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054;
2. State Key Laboratory of Causes and Prevention of High Incidence in Central Asia, Clinical Medicine Research Institute, the First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, Xinjiang, China

Received:2022-06-20 Revised:2022-10-22 Published:2022-12-03

摘要/Abstract

摘要： 目的：检测哈萨克族食管鳞癌患者的癌组织及其癌旁正常组织人型半胱氨酸蛋白酶抑制剂cystatin 6(cystatin M/E，CST6)的蛋白表达水平，并分析其与临床病理指标和预后之间的关系。方法：收集2010年12月—2020年12月行食管癌根治术的55例哈萨克族食管鳞癌患者癌组织及癌旁正常组织标本，采用免疫组织化学染色法检测其CST6蛋白的表达情况。χ²检验分析CST6蛋白表达和患者临床病理指标之间的关系，Kaplan-Meier单因素和COX多因素分析影响食管癌预后的危险因素。结果：CST6蛋白的表达主要定位于细胞质、细胞膜以及角化区。食管鳞癌组织中CST6蛋白的阳性表达率为36.4%(20/55)，癌旁正常组织中的阳性表达率为63.6%(35/55)，差异具有统计学意义(χ²=9.032，P=0.003)。CST6蛋白的表达水平与家族史(P=0.045)和肿瘤分化程度(P=0.036)有关，无肿瘤家族史以及肿瘤高分化的患者其阳性表达率更高。Kaplan-Meier生存分析发现，CST6蛋白的表达水平与患者的总生存率有关(P<0.05)。结论：CST6蛋白在哈萨克族食管鳞癌患者中呈低表达，CST6的低表达可能是哈萨克族食管鳞癌发病及不良预后的危险因素之一。

关键词: 哈萨克族, 食管鳞癌, 半胱氨酸组织蛋白酶抑制剂, 抑癌基因, 预后

Abstract: OBJECTIVE:To study expression of the cystatin 6 (CST6) protein in esophageal squamous cell carcinomas among Kazakhs,and to explore its relationship with clinicopathological parameters and prognosis. METHODS:From December 2010 to December 2020,tissues from 55 Kazakh patients who had esophagectomy at the First Affiliated Hospital of Xinjiang Medical University were collected. Expression of CST6 in cancer and corresponding paracancerous tissues was detected by immunohistochemical method. Relationships between its expression and clinicopathological features was analyzed by χ² test,Kaplan-Meier univariate analysis and COX multivariate analysis to evaluate their relationships with prognosis of esophageal cancer. RESULTS:Expression of the CST6 protein was mainly located in the cytoplasm,cell membrane and keratinized area. The levels of expression of CST6 were 36.4% in the cancer and 63.6% in the corresponding paracancerous tissues. The difference was statistically significant (χ²=9.032,P=0.003). CST6 expression was related to family history (P=0.045) and tumor differentiation (P=0.036):higher in patients with no family history of tumor and with well-differentiated tumors. Kaplan-Meier survival analysis showed that the expression was related to the survival rates of patients (P<0.05):the average survival time of patients with high CST6 expression was longer. Cox multivariant survival analysis showed that negative expression was an independent risk factor for poor prognosis. CONCLUSION:CST6 protein was significantly under-expressed in esophageal squamous cell carcinoma among Kazakh patients. The protein therefore may play a tumor suppression role and its negative expression was a risk factor for poor prognosis.

Key words: Kazakh, esophageal squamous cell carcinoma, tumor suppressor gene, CST6, prognosis

中图分类号:

R735.1

李子垚, 张海平, 买地尼也提·尼亚孜, 居来提·艾尼瓦尔, 张力为, 伊地力斯·阿吾提. Cystatin 6蛋白在哈萨克族食管鳞癌组织中的表达及其意义[J]. 癌变·畸变·突变, 2022, 34(6): 429-433,438.

LI Ziyao, ZHANG Haiping, MADINIYET·Niyaz, JULATI·Ainiwaer, ZHANG Liwei, EDRIS·Awut. Clinicopathological significance of cystatin 6 protein expression in Kazakh esophageal squamous cell carcinoma[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(6): 429-433,438.

参考文献

[1] 王宁, 刘硕, 杨雷, 等. 2018全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志, 2019, 5(1):87-97.
[2] KARAMANOU M, MARKATOS K, PAPAIOANNOU T G, et al. Hallmarks in history of esophageal carcinoma[J]. J BUON, 2017, 22(4):1088-1091.
[3] CHEN W Q, ZHENG R S, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA A Cancer J Clin, 2016, 66(2):115-132.
[4] LIN Y S, TOTSUKA Y, HE Y T, et al. Epidemiology of esophageal cancer in Japan and China[J]. J Epidemiol, 2013, 23(4):233-242.
[5] 马莉莉, 张树丽, 李琴, 等. 新疆哈萨克族食管癌与正常组织间差异表达miRNA的筛查及验证[J]. 癌变·畸变·突变, 2020, 32(1):52-56.
[6] SOTIROPOULOU G, ANISOWICZ A, SAGER R. Identifi-cation, cloning, and characterization of cystatin M, a novel cysteine proteinase inhibitor, down-regulated in breast cancer[J]. J Biol Chem, 1997, 272(2):903-910.
[7] ABRAHAMSON M, BARRETT A J, SALVESEN G, et al. Isolation of six cysteine proteinase inhibitors from human urine. Their physicochemical and enzyme kinetic properties and concentrations in biological fluids[J]. J Biol Chem, 1986, 261(24):11282-11289.
[8] ZHANG J, SHRIDHAR R, DAI Q, et al. Cystatin m:a novel candidate tumor suppressor gene for breast cancer[J]. Cancer Res, 2004, 64(19):6957-6964.
[9] VEENA M S, LEE G, KEPPLER D, et al. Inactivation of the cystatin E/M tumor suppressor gene in cervical cancer[J]. Genes Chromosomes Cancer, 2008, 47(9):740-754.
[10] AZIMI A, LO K, KIM J, et al. Investigating proteome changes between primary and metastatic cutaneous squamous cell carcinoma using SWATH mass spectrometry[J]. J Dermatol Sci, 2020, 99(2):119-127.
[11] LALMANACH G, KASABOVA-ARJOMAND M, LECAILLE F, et al. Cystatin M/E (cystatin 6):a Janus-faced cysteine protease inhibitor with both tumor-suppressing and tumor-promoting functions[J]. Cancers, 2021, 13(8):1877.
[12] JIN L, ZHANG Y, LI H, et al. Differential secretome analysis reveals CST6 as a suppressor of breast cancer bone metastasis[J]. Cell Res, 2012, 22(9):1356-1373.
[13] AMIN M B, GREENE F L, EDGE S B, et al. The Eighth Edition AJCC Cancer Staging Manual:continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging[J]. CA A Cancer J Clin, 2017, 67(2):93-99.
[14] 刘培, 黄勇. 食管癌分子生物学的研究进展[J]. 现代医药卫生, 2007, 23(5):677-679.
[15] 孟君, 刘丽华, 单保恩. 蛋白质组学与食管癌关系的研究进展[J]. 癌变·畸变·突变, 2010, 22(6):488-490.
[16] BOMAN H G. Gene-encoded peptide antibiotics and the concept of innate immunity:an update review[J]. Scand J Immunol, 1998, 48(1):15-25.
[17] ZEEUWEN P L, VAN VLIJMEN-WILLEMS I M, JANSEN B J, et al. Cystatin M/E expression is restricted to differentiated epidermal keratinocytes and sweat glands:a new skin-specific proteinase inhibitor that is a target for cross-linking by transglutaminase[J]. J Invest Dermatol, 2001, 116(5):693-701.
[18] ZHANG J, SHRIDHAR R, DAI Q, et al. Cystatin m:a novel candidate tumor suppressor gene for breast cancer[J]. Cancer Res, 2004, 64(19):6957-6964.
[19] SHRIDHAR R, ZHANG J, SONG J, et al. Cystatin M suppresses the malignant phenotype of human MDA-MB-435S cells[J]. Oncogene, 2004, 23(12):2206-2215.
[20] VIGNESWARAN N, WU J, NAGARAJ N, et al. Silencing of cystatin M in metastatic oral cancer cell line MDA-686Ln by siRNA increases cysteine proteinases and legumain activities, cell proliferation and in vitro invasion[J]. Life Sci, 2006, 78(8):898-907.
[21] KEPPLER D. Towards novel anti-cancer strategies based on cystatin function[J]. Cancer Lett, 2006, 235(2):159-176.
[22] ZEEUWEN P L J M, CHENG T, SCHALKWIJK J. The biology of cystatin M/E and its cognate target proteases[J]. J Investig Dermatol, 2009, 129(6):1327-1338.
[23] LALMANACH G, KASABOVA-ARJOMAND M, LECAILLE F, et al. Cystatin M/E (cystatin 6):a Janus-faced cysteine protease inhibitor with both tumor-suppressing and tumor-promoting functions[J]. Cancers, 2021, 13(8):1877.
[24] QIU J X, AI L B, RAMACHANDRAN C, et al. Invasion suppressor cystatin E/M (CST6):high-level cell type-specific expression in normal brain and epigenetic silencing in gliomas[J]. Lab Invest, 2008, 88(9):910-925.
[25] KIM T Y, ZHONG S, FIELDS C R, et al. Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma[J]. Cancer Res, 2006, 66(15):7490-7501.

Cystatin 6蛋白在哈萨克族食管鳞癌组织中的表达及其意义

Clinicopathological significance of cystatin 6 protein expression in Kazakh esophageal squamous cell carcinoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李燕, 董经茹, 魏媛媛, 张金艳. 极光激酶A在宫颈鳞状细胞癌患者血清中的表达及其临床意义[J]. 癌变·畸变·突变, 2022, 34(6): 421-428.
[2]	于运亮, 王莉莉, 李婷, 封建凯. 嘌呤能受体X1与肺腺癌预后及免疫细胞浸润的相关性研究[J]. 癌变·畸变·突变, 2022, 34(5): 353-360,365.
[3]	张海智, 温晓芬, 黄彬亮, 林慧, 薛文武, 曾德, 林丹霞. 溶质载体超家族50蛋白在乳腺癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2022, 34(5): 373-377.
[4]	张玉铃, 刘迪填, 陈春发. CD68巨噬细胞浸润对原发性食管小细胞癌预后的影响[J]. 癌变·畸变·突变, 2022, 34(4): 279-283.
[5]	王绪娟, 罗永鑫, 李陈强, 王汝晋, 郑婷婷. 术前检查指标dNLR、SII、CRP/ALB对乳腺癌复发转移的预测价值[J]. 癌变·畸变·突变, 2022, 34(4): 284-288,323.
[6]	冯志寅, 吴怡娴, 哈晓丹, 陈邬锦, 李秀梅, 董娟娟. 食管癌高发人群血浆游离DNA中的p38MAPK基因检测研究[J]. 癌变·畸变·突变, 2022, 34(2): 105-109.
[7]	梁峰, 张玮, 李飞, 王胜杰, 杜宇晶, 张迎春. 长链非编码RNACASC9在结直肠癌组织中的表达及其临床意义[J]. 癌变·畸变·突变, 2022, 34(2): 110-113.
[8]	彭友彬, 林浩, 黎明, 黄海花. TPX2在非肌层浸润性膀胱癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2022, 34(1): 30-34.
[9]	焦文鹏, 侯琳, 崔妹娟, 焦文静, 马鸣, 张金艳. miR-93-5p和miR-106b-5p在酒精相关性肝癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2021, 33(6): 430-434.
[10]	高晓斌, 武雪亮, 王胜杰, 孙光源, 王文静, 梁峰, 赵轶峰, 刘振显, 张迎春. TRIM59在结直肠癌中的表达及其与临床病理指标的关系[J]. 癌变·畸变·突变, 2021, 33(6): 446-450.
[11]	杨兴肖, 张雪原, 邹乃祎, 单保恩, 马鸣, 祝淑钗. 干扰HMGB1基因表达对食管鳞癌细胞侵袭迁移及放射敏感性的影响[J]. 癌变·畸变·突变, 2021, 33(5): 327-333.
[12]	杨荔艳, 刘奏, 郝佳洁, 张钰, 王明荣. p62蛋白在食管鳞癌细胞中核浆易位的机制研究[J]. 癌变·畸变·突变, 2021, 33(5): 338-344.
[13]	焦文静, 张金艳, 马鸣, 郭秀娟, 冯军花, 邵俊国, 焦文鹏. 异黏蛋白与叉头框蛋白M1在肝细胞癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2021, 33(5): 349-353,359.
[14]	常晨, 杨荔艳, 蔡洪庆, 苑青, 郝佳洁, 王明荣. 食管鳞癌中SERPINE1 mRNA的表达及其临床意义[J]. 癌变·畸变·突变, 2021, 33(4): 245-249.
[15]	张世民, 赵瑞君. 蛋白酪氨酸磷酸酶受体J在乳腺癌组织中的表达及其与临床预后的相关性[J]. 癌变·畸变·突变, 2021, 33(4): 276-279,285.